RNAi mediated inhibition of beta-catenin demonstrates anti-tumor efficacy and immune microenvironment modulation in preclinical hepatocellular carcinoma models

被引：0
|
作者：
Dadali, Tulin
Miller, Spencer
Saawant, Gaurav
Abbott, Stephen
Yu, Mikyung
Morskaya, Svetlana
Lehrich, Brandon
Monga, Satdarshan
Lau, Gloria
Maier, Martin
Broom, Wendy
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5924
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5924
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ST316, a clinical peptide antagonist of beta-catenin, induces anti-tumor immune responses by multiple mechanisms of action
    Scuoppo, Claudio
    Mendelson, Karen
    Ramirez, Ricardo
    Koester, Mark
    Diehl, Julia
    Gallagher, Erin
    Leong, Siok
    Gonzales, Jerel
    Mattes, Zach
    Ghamsari, Lila
    Merutka, Gene
    Kappel, Barry J.
    Vainstein-Haras, Abi
    Rotolo, Jim A.
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis
    Shi, Le
    Yang, Fan
    Luo, Fei
    Liu, Yi
    Zhang, Feng
    Zou, Meijuan
    Liu, Qizhan
    TUMOR BIOLOGY, 2016, 37 (09) : 12791 - 12803
  • [23] RNAi-mediated beta-catenin inhibition to promote T-cell infiltration and antitumor activity in combination with immune checkpoint blockade.
    Ganesh, Shanthi
    Shui, Serena
    Lai, Cheng
    Dudek, Hank
    Wang, Weimin
    Brown, Bob D.
    Abrams, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] The immune-modulation of HM16390, firing up the poor tumor microenvironment to induce a potent anti-tumor efficacy
    Jeong, Seongju
    Kim, Yunjae
    Byun, Jooyun
    Kim, Jinyoung
    Choi, Jaehyuk
    Bae, Sungmin
    Kim, Daejin
    Choi, In Young
    CANCER RESEARCH, 2024, 84 (07)
  • [25] Targeting TBL1 with tegavivint promotes anti-tumor and immunomodulatory responses in preclinical models of hepatocellular carcinoma
    Holloway, Kimberly R.
    Drake, Thomas
    Bird, Thomas
    Horrigan, Stephen
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma
    Won Kim
    Jung-Hwan Yoon
    Jung-Ryul Kim
    In-Jin Jang
    Yung-Jue Bang
    Yoon-Jun Kim
    Hyo-Suk Lee
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 497 - 507
  • [27] Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma
    Kim, Won
    Yoon, Jung-Hwan
    Kim, Jung-Ryul
    Jang, In-Jin
    Bang, Yung-Jue
    Kim, Yoon-Jun
    Lee, Hyo-Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (03) : 497 - 507
  • [28] Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
    Sang Hyun Seo
    Kyung Joo Cho
    Hye Jung Park
    Hye Won Lee
    Beom Kyung Kim
    Jun Yong Park
    Do Young Kim
    Sang Hoon Ahn
    Jae Hee Cheon
    Jong In Yook
    Man-Deuk Kim
    Dong Jin Joo
    Seung Up Kim
    Cell Communication and Signaling, 21
  • [29] Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
    Seo, Sang Hyun
    Cho, Kyung Joo
    Park, Hye Jung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Cheon, Jae Hee
    Yook, Jong In
    Kim, Man-Deuk
    Joo, Dong Jin
    Kim, Seung Up
    CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
  • [30] Varlitinib demonstrates tumor regression and vessel normalization in ErbB-dependent and mutated beta-catenin hepatocellular carcinoma patient-derived xenograft model
    Shuen, Wai Ho
    Ong, Richard
    Yeo, Chloe
    Banu, Rebecca
    Koh, Lip Seng
    Chee, Chit Lai
    Seet, Qihui
    Ooi, Lisa
    McHale, Mark
    Lindmark, Bertil
    Toh, Han Chong
    Hung, Huynh
    CANCER RESEARCH, 2018, 78 (13)
12345